Evaluate

Cell, gene, and nucleic acid therapies have been through plenty of cycles of excitement and doubt, and this latest one is more selective. Advanced therapies pipeline growth has slowed from 25% in 2021 to 7% in 2025, and several high-profile launches have

A sell-side analyst tells a small or mid-cap healthcare company they are interested. The science is compelling, the data look promising, and management is accessible. Then nothing happens. The initiation report never comes. The cause is usually economics,

There are more than a thousand publicly traded healthcare companies on US exchanges alone. Globally, hundreds more are listed on the LSE, Euronext, and exchanges across Asia-Pacific. Together they represent trillions of dollars in market value, thousands

The branded cardiovascular market is forecast to grow at 11% a year between 2025 and 2032, well ahead of the 7% forecast for prescription drugs overall. That growth is fueled through new products across novel mechanisms and modalities, and the 2032 rankin

RealityBench: simulated worlds to evaluate a vision language model's ability to document human physical work.

We're always delighted to welcome new people into the fold at Evaluate, particularly when they bring a new perspective on a critical part of the life sciences market. Today's subject of Meet the Team is Brian Bock, Leader of Strategic Broker Partnerships

As a biotech approaches commercial launch, the forecast often still carries the shape it was given in the early days: built by finance, before a commercial team existed. In this video, I explain why adding a commercial perspective as launch nears is criti

Most people in pharma are aware that R&D costs are rising, both in dollar terms and in development timelines. But the reaction is less well-known: risk is being front loaded to Phase I and relative success rates have fallen by around 15%. More promisingly

Immunology is one of pharma's most valuable and fastest-growing therapy areas, with forecast compound annual growth of over 9% and anticipated combined sales of $200 billion by 2032. Multi-indication immunology blockbusters dominate the landscape across m